MedTrace Logo

A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function

NCT04486482 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2021-08-13

No results posted yet for this study

Summary

This exploratory, open-label clinical study aims to explore the physiologic effects of KB109, a novel glycan, on adult patients with COVID-19 illness on gut microbiota structure and function in the outpatient setting.

Conditions

  • Mild-to-Moderate COVID-19

Interventions

OTHER

KB109 + Self Supportive Care (SSC)

KB109 is a novel glycan

OTHER

Self Supportive Care (SSC) Alone

Self Supportive Care (SSC) Alone

Sponsors & Collaborators

  • Kaleido Biosciences

    lead INDUSTRY

Principal Investigators

  • Mark Wingertzahn, PhD · Kaleido Biosciences

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-12
Primary Completion
2021-03-30
Completion
2021-03-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04486482 on ClinicalTrials.gov